Results 21 to 30 of about 40,229 (203)

Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt

open access: yesAntibiotics, 2021
The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study.
Ragaey A. Eid   +6 more
doaj   +1 more source

Cefepime-induced encephalopathy

open access: yesНеврология, нейропсихиатрия, психосоматика, 2023
Cefepime is a fourth-generation cephalosporin antibiotic widely used in clinical practice for various organ systems pathology treatment. The article describes the clinical observation of a patient who, 3 days after cefepime administration, had a decrease
T. N. Pushkar   +3 more
doaj   +1 more source

Probable Stevens-Johnson Syndrome During Taletrectinib Treatment After Crizotinib-Related Rash in ROS1-Positive Lung Cancer. [PDF]

open access: yesRespirol Case Rep
Probable Stevens–Johnson syndrome developed during taletrectinib treatment after a preceding crizotinib‐related Grade 3 rash in a patient with ROS1‐rearranged lung adenocarcinoma. This case highlights that severe cutaneous adverse reactions should be considered when fever and neutropenia occur during ROS1‐TKI therapy.
Yasui H   +12 more
europepmc   +2 more sources

Carbapenem-Sparing Strategies for ESBL Producers: When and How

open access: yesAntibiotics, 2020
Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections.
Ilias Karaiskos, Helen Giamarellou
doaj   +1 more source

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates

open access: yes, 2023
Background Aztreonam/avibactam is one of the last therapeutic options for treating infections caused by NDM-like-producing Enterobacterales.
Laurent Poirel   +11 more
core   +1 more source

Prevalence and genetics of cefepime resistance among the AmpC-producing organisms Citrobacter freundii complex, Enterobacter cloacae complex, and Klebsiella aerogenes

open access: yesAntimicrobial Agents and Chemotherapy
Cefepime is generally recommended for treatment of clinically significant AmpC producers, including Citrobacter freundii complex (Cfre), Enterobacter cloacae complex (Eclo), and Klebsiella aerogenes (Kaer).
Sarah M. Schrader   +4 more
doaj   +1 more source

Cefepime versus Ceftriaxone for Empiric Treatment of Hospitalized Patients with Community-Acquired Pneumonia

open access: yes, 1998
Effective empiric treatment of pneumonia requires antibiotic coverage against gram-negative and gram-positive pathogens, including drug-resistant isolates.
Nelson, M   +2 more
core   +1 more source

Cefepime/Enmetazobactam

open access: yesHospital Pharmacy
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees.
Andrew R. Staten, Danial E. Baker
openaire   +2 more sources

Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections [PDF]

open access: yes, 2020
BACKGROUND: β-Lactam (BL)/β-lactamase inhibitor (BLI) combinations are widely used for the treatment of Gram-negative infections. Cefepime has not been widely studied in combination with BLIs. Sulbactam, with dual BL/BLI activity, has been partnered with
Momin, MHFA   +4 more
core   +2 more sources

Home - About - Disclaimer - Privacy